Associate Editor, Ophthalmology Times
US Federal Trade Commission files a lawsuit to block Amgen’s acquisition of Horizon Therapeutics
May 18th 2023The lawsuit states the $27.8 billion acquisition would allow Amgen to strengthen their drug portfolio and stifle drug competition in a bid to monopolize two fast-growing medications.
Read More
ASCRS 2023: Study of standalone multiple trabecular micro-bypass stents for uncontrolled glaucoma
May 6th 2023Ike Ahmed, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation on the study of standalone multiple trabecular micro-bypass stents for uncontrolled glaucoma at the ASCRS annual meeting in San Diego
Read More
ASCRS 2023: Antibiotic resistance of intraocular bacterial pathogens
May 6th 2023Penny Asbell, MD, FACS, MBA, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation on the ARMOR study and the antibiotic resistance of intraocular bacterial pathogens at the ASCRS annual meeting in San Diego
Read More
ARVO 2023: Implementing dropless cataract surgery to drop the cost
May 3rd 2023Ravi Parikh, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation about adopting dropless cataract surgery to help reduce cost to both patients and the healthcare system at this year's ARVO meeting.
Read More
ARVO 2023: Machine learning to identify structural phenotypes for glaucoma
May 3rd 2023Nazlee Zebardast, MD, MSc sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her research on using machine learning methods to identify image-based, specifically OCT based, phenotypes or structural phenotypes for glaucoma. at this year's ARVO meeting.
Read More
ARVO 2023: ViaLase's FLigHT for non-incisional glaucoma treatment
May 3rd 2023Eric Mikula, PhD, from ViaLase sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss the company's femtosecond laser image-guided high-precision trabeculectomy, FLigHT, for non-incisional glaucoma treatment at this year's ARVO meeting.
Read More
ARVO LIVE: Using mitochondria, senolytic agents to treat retinal injury
May 3rd 2023Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.
Read More
ARVO LIVE: CEO of RetinAI gives update on technological advances in ophthalmology
May 2nd 2023Ophthalmology Times® talked with Carlos Ciller, PhD, the co-founder and CEO of RetinAI, about technological advances the company is making to drive innovation and to accelerate drug development pipelines at this year's ARVO meeting.
Read More
ARVO LIVE: AI revolution in ophthalmology
May 2nd 2023Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year's ARVO meeting.
Read More
ARVO LIVE: Epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells
April 27th 2023Ophthalmology Times® talked with Bruce Ksander, PhD, about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells at this year's ARVO meeting.
Read More